Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation

Fryderyk Lorenz, Stefan Marklund, Mårten Werner, Richard Palmqvist, Björn Engelbrekt Wahlin, Anders Wahlin, Fryderyk Lorenz, Stefan Marklund, Mårten Werner, Richard Palmqvist, Björn Engelbrekt Wahlin, Anders Wahlin

Abstract

The diagnosis of gastrointestinal graft versus host disease (GI-GVHD) is based on clinical symptoms and histological findings. In clinical practice, it is often difficult to decide whether abdominal symptoms in an allogeneic transplant recipient are caused by GVHD or other disorders. Endoscopic biopsies are helpful in establishing the diagnosis, but endoscopy is not always possible to perform due to poor general condition of the patients. No biomarkers are routinely used to predict GVHD. The aim of fecal calprotectin and alpha-1 antitrypsin testing in our study was to find out whether determination of the concentrations of these proteins may be used as a screening method for enteric GVHD. We studied prospectively 51 patients, 8 of whom developed GI-GVHD. Our data demonstrate that elevated fecal calprotectin levels were significantly associated with presence of GI-GVHD. We found a positive association between high F-calprotectin and severe gastrointestinal GVHD. In bivariate analysis, only calprotectin but not alpha-1 antitrypsin was independently associated with GI-GVHD. Testing for fecal calprotectin after allogeneic stem cell transplantation may be a useful screening tool.

Figures

Figure 1. Calprotectin was significantly higher in…
Figure 1. Calprotectin was significantly higher in patients with GI-GVHD than in patients without GI-GVHD (p = 0.016).
Alpha-1 antitrypsin was also higher among patients with GI-GVHD (p = 0.058).

References

    1. Kolb H. J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 112, 4371–83 (2008).
    1. Ferrara J. L., Levine J. E., Reddy P. & Holler E. Graft-versus-host disease. Lancet. 373, 1550–61 (2009).
    1. Jagasia M. et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 119, 296–307 (2012).
    1. Kreisel W. et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant. 47, 430–8 (2012).
    1. Washington K. & Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum. Pathol. 40, 909–17 (2009).
    1. Lin J., Fan R., Zhao Z., Cummings O. W. & Chen S. Is the presence of 6 or fewer crypt apoptotic bodies sufficient for diagnosis of graft versus host disease? A decade of experience at a single institution. Am. J. Surg. Pathol. 37, 539–47 (2013).
    1. Bonnín A., Tomàs M. & Vidal V. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev. Esp. Enferm. Dig. (Madrid) 99, 689–93 (2007).
    1. Yui S., Nakatani Y. & Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with broad apoptosis-inducing activity. Biol. Pharm. Bull. 26, 753–60 (2003).
    1. Yeh S. P. & Liao Y. M. Gastric bleeding due to graft-vs-host disease. Discrepancy between endoscopic and histologic assessment. Am. J. Clin. Pathol. 122, 919–25 (2004).
    1. Glaser C. B., Karic L. & Cohen A. B. Low pH stability of alpha-1-antititrypsin. Biochim. Biophys. Acta. 491, 325–30 (1997).
    1. Lerner K. G., Kao G. F., Buckner C. D., Clift R. A. & Thomas E. D. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A–matched sibling donors. Transplant. Proc. 6, 367–71 (1974).
    1. Bastos Oreiro M. et al. Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. Bone Marrow Transplant. 47, 1241–2 (2012).
    1. Rodriguez-Otero P. et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 119, 5909–17 (2012).
    1. Chiusolo P. et al. Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. Blood. 120, 4443–4 (2012).
    1. Montalto M. & Gallo A. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J. Gastroenterol. 16, 3406–10 (2010).
    1. Sipponen T. et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol. Ther. 28, 1221–9 (2008).

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever